Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC3 | Q13489 | 8/20 | 0.34 |
| ▸ | XIAP | P98170 | 6/20 | 0.34 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
| ▸ | BIRC7 | Q96CA5 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 7/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL819050 | 1.00 | BIRC3 (0.34) | BIRC3XIAPBIRC2BIRC7CYP3A4 | |
| SCHEMBL12405720 | 0.93 | BIRC3 (0.39) | BIRC3XIAPBIRC2BIRC7TNF | |
| SCHEMBL15501147 | 0.93 | BIRC3 (0.39) | BIRC3XIAPBIRC2BIRC7TNF | |
| SCHEMBL12474013 | 0.90 | BIRC3 (0.38) | BIRC3XIAPBIRC2BIRC7TNF | |
| SCHEMBL818120 | 0.90 | BIRC3 (0.34) | BIRC3XIAPBIRC2BIRC7TNF | |
| SCHEMBL820303 | 0.90 | BIRC3 (0.34) | BIRC3XIAPBIRC2BIRC7TNF | |
| SCHEMBL818119 | 0.90 | BIRC3 (0.37) | BIRC3XIAPBIRC2BIRC7TNF | |
| SCHEMBL10109908 | 0.88 | BIRC3 (0.47) | BIRC3XIAPBIRC2BIRC7TNF | |
| SCHEMBL820692 | 0.86 | SCN9A (0.35) | — | |
| SCHEMBL820542 | 0.85 | BIRC3 (0.33) | BIRC3XIAPBIRC2BIRC7TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288116-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUITCAL CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288116-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUITCAL CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2009094287-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICAL CORPORATION (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288116-A1 | IAP INHIBITORS | XIAP, BIRC5, BIRC7 | BIRC3 6/4885XIAP 1/4885BIRC2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.